10x Genomics, Inc. is trading 5.5% up at $33.89 as the stock extends gains following the announcement of a multi-year bladder cancer research collaboration with Cleveland Clinic.
- The partnership has driven sustained buying interest, continuing an upside move that originated with a rally on June 15.
- Shares remain well-supported despite a quiet macro and news calendar, highlighting the significant impact of the recent clinical collaboration news.